Introduction: It is well-known that circulating microRNAs (miRNAs) play a relevant role in many kinds of diseases by regulating the expression of genes involved in various pathophysiologic processes, including erectile dysfunction (ED) and cardiovascular diseases (CVD). Purpose: This study aimed to identify the miRNA-21 profile in the blood samples of patients with ED, CVD, and the combination of both pathologies to elucidate the potential function of miRNA-21. Methods: A total of 45 patients with CVD and/or who underwent the erectile function test were included and divided into the following categories: CVD with ED (cases, n = 29) and controls (n = 16) with either ED or CVD. Real-time polymerase chain reaction analysis verified the results. miRNA-21 expression was quantified, and informatics analysis was applied to predict the functions of this differentially expressed miRNA-21. Results: A total of 64% of cases (63 ± 9 years, 66% with severe ED, 56% with CV ejection fraction) first presented ED as the sentinel clinical manifestation. Serum miRNA-21 levels in the control ED were significant, up to 10-fold higher than in the CVD controls and cases. A significant inverse (p = 0.0368, β = −2.046) correlation was found between erectile function and miRNA-21 levels. Conclusions: Our study provides comprehensive insights into the functional interaction between miRNA-21 and ED in CVD patients. Its relevance lies in the potential of miRNA as a biomarker to be applied in the cardiovascular predictive medicine field.

Circulating miRNA-21 is an innovative biomarker for cardiovascular events in erectile dysfunction patients / Agulló, Laura; Segura, Ana; Ortuño-Miquel, Samanta; Brinca, Ana Teresa; Micol-Ponce, Rosa; Arrarte, Vicente; Ponce, María Rosa; Miró-Martínez, Pau; Zandonai, Thomas; Peiró, Ana M.. - In: FRONTIERS IN CARDIOVASCULAR MEDICINE. - ISSN 2297-055X. - 11:1301925(2024). [10.3389/fcvm.2024.1301925]

Circulating miRNA-21 is an innovative biomarker for cardiovascular events in erectile dysfunction patients

Zandonai, Thomas;
2024-01-01

Abstract

Introduction: It is well-known that circulating microRNAs (miRNAs) play a relevant role in many kinds of diseases by regulating the expression of genes involved in various pathophysiologic processes, including erectile dysfunction (ED) and cardiovascular diseases (CVD). Purpose: This study aimed to identify the miRNA-21 profile in the blood samples of patients with ED, CVD, and the combination of both pathologies to elucidate the potential function of miRNA-21. Methods: A total of 45 patients with CVD and/or who underwent the erectile function test were included and divided into the following categories: CVD with ED (cases, n = 29) and controls (n = 16) with either ED or CVD. Real-time polymerase chain reaction analysis verified the results. miRNA-21 expression was quantified, and informatics analysis was applied to predict the functions of this differentially expressed miRNA-21. Results: A total of 64% of cases (63 ± 9 years, 66% with severe ED, 56% with CV ejection fraction) first presented ED as the sentinel clinical manifestation. Serum miRNA-21 levels in the control ED were significant, up to 10-fold higher than in the CVD controls and cases. A significant inverse (p = 0.0368, β = −2.046) correlation was found between erectile function and miRNA-21 levels. Conclusions: Our study provides comprehensive insights into the functional interaction between miRNA-21 and ED in CVD patients. Its relevance lies in the potential of miRNA as a biomarker to be applied in the cardiovascular predictive medicine field.
2024
1301925
Agulló, Laura; Segura, Ana; Ortuño-Miquel, Samanta; Brinca, Ana Teresa; Micol-Ponce, Rosa; Arrarte, Vicente; Ponce, María Rosa; Miró-Martínez, Pau; Zandonai, Thomas; Peiró, Ana M.
Circulating miRNA-21 is an innovative biomarker for cardiovascular events in erectile dysfunction patients / Agulló, Laura; Segura, Ana; Ortuño-Miquel, Samanta; Brinca, Ana Teresa; Micol-Ponce, Rosa; Arrarte, Vicente; Ponce, María Rosa; Miró-Martínez, Pau; Zandonai, Thomas; Peiró, Ana M.. - In: FRONTIERS IN CARDIOVASCULAR MEDICINE. - ISSN 2297-055X. - 11:1301925(2024). [10.3389/fcvm.2024.1301925]
File in questo prodotto:
File Dimensione Formato  
fcvm-11-1301925-2.pdf

accesso aperto

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Creative commons
Dimensione 305.62 kB
Formato Adobe PDF
305.62 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/406280
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact